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Background:Collagen type IV is themajor constituent of basementmembranes underlying endothelial cells and is
important for endothelial cell attachment and function. Autoantibodies against native collagen type IV have been
found in various autoimmune diseases. Oxidation of LDL in the vascular wall results in the formation of reactive
aldehydes, which could modify surrounding matrix proteins. Like oxidized LDL, these modiﬁed matrix proteins
are likely to induce immune responses. We examined whether autoantibodies against native or aldehyde-
modiﬁed collagen type IV are associated with myocardial infarction.
Methods: IgM and IgG against native and aldehyde-modiﬁed collagen type IV were measured by ELISA in serum
from 387 survivors of a ﬁrst myocardial infarction and 387 age- and sex-matched controls.
Results: Post-infarction patients had signiﬁcantly increased levels of IgM against native collagen type IV, and
IgG against native collagen type IV was present at detectable level in 17% of patients as opposed to 7% of
controls (p b 0.001). Controlling for major cardiovascular risk factors demonstrated that the presence of
IgG against native collagen type IV was associated with myocardial infarction (OR 2.9 (1.6–5.4), p =
0.001). Similarly, subjects in the highest quartile of IgM against native collagen type IV had increased risk
of having suffered myocardial infarction (OR 3.11 (1.8–5.4), p b 0.001) after adjusting for cardiovascular
risk factors. In contrast, IgG against aldehyde-modiﬁed collagen type IV was decreased in myocardial infarc-
tion patients, but this association was not independent of established cardiovascular risk factors.
Conclusion: Autoantibodies against collagen type IV are associated with myocardial infarction independent-
ly of traditional cardiovascular risk factors.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute coronary events mainly arise from plaque rupture or plaque
erosion [1]. Plaques prone to rupture are characterized by a large
lipid-rich necrotic core with an overlying thin ﬁbrous cap [1], which is
believed to rupture due to increased inﬂammation resulting in the deg-
radation of extracellular matrix components. The mechanisms for
plaque erosion are not known, but lesions are characterized by the
absence of endothelium [1]. The endothelium regulates the vascularAtherosclerosis Research Unit,
171 76 Sweden. Tel.: +46 8
8.
liability and freedom from bias
land Ltd. This is an open access articltone, controls blood coagulation and regulates inﬂammatory processes
[2]. Endothelial dysfunction predicts clinical events caused by athero-
thrombosis, and case–control studies indicate an association between
endothelial dysfunction and acute coronary syndromes [2,3]. Although
endothelial dysfunction clinically is measured by parameters of vasodi-
lation, it appears that this condition is equated with a loss of
atheroprotection and promotion of atherothrombosis.
Endothelial cells are lying on and adhere to the basement mem-
brane, a thin sheet of extracellular matrix. The main component of
the basement membrane is the network forming collagen type IV,
which comprises 50% of the basement membrane. Collagen type IV
binds to cells via integrins on the cell surface or via discoidin domain
receptors [4–7]. As expected, the collagen type IV interaction with
endothelial cells is important for maintaining endothelial cell func-
tion [8]. Interestingly, autoantibodies against collagen type IV are
present in various inﬂammatory and autoimmune diseases [9–13].e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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associated with diabetes and development of microangiopathy [14]
and have also been reported in patients with systemic vasculitis
and Crohn's disease [13,15]. Moreover, autoantibodies against colla-
gen type IV have been detected in children with type 1 diabetes and
hypertension [16,17].
Accumulation and oxidation of LDL in the vessel wall are consid-
ered as key events in the development of atherosclerotic lesions [18].
Thus, efforts so far have almost exclusively been focused on charac-
terizing modiﬁcations of the LDL particles. Oxidation of fatty acids
in LDL leads to the formation of reactive aldehydes, such as
malondialdehyde (MDA) [19]. These aldehydes react with the LDL
protein apoB100, and MDA-modiﬁed apoB100 becomes a target for
the immune system. Accordingly, autoantibodies against oxidized
LDL are associated with cardiovascular disease [19]. We have previ-
ously shown that during oxidation of LDL, reactive aldehydes leak
out of the LDL particle and modify surrounding extracellular matrix
proteins [20]. These modiﬁcations on extracellular matrix may im-
pair structural and cell-binding properties of the proteins, resulting
in decreased plaque stability. It is also possible that modiﬁcation of
basement membrane proteins enhances inﬂammation, as shown by
increasedmonocyte attachment and intracellular adhesion molecule
(ICAM)-1 expression on endothelial cells attached to oxidized lami-
nin [21]. Similar to oxidized LDL, modiﬁed matrix proteins are likely
to result in immune responses against the extracellular matrix in the
plaque. Indeed, we have identiﬁed autoantibodies against several
aldehyde-modiﬁed matrix proteins, including MDA-modiﬁed lami-
nin present in basement membranes. Interestingly, these autoanti-
bodies were associated with less cardiovascular disease in a
prospective cohort, which may imply a protective effect in humans
[22].
In the present work, we investigated the presence of autoantibodies
against native and aldehyde-modiﬁed collagen type IV in patients with
a recent myocardial infarction (MI) and population-based matched
controls.2. Methods
2.1. Cohort
The Stockholm Coronary Atherosclerosis Risk Factor (SCARF) study
database and biobankwere used for the present study. As reported else-
where [23], 387 survivors of a ﬁrst MI aged less than 60 years were
recruited along with 387 age- and sex-matched controls from the
general population of the same county. In both groups 82% of the sub-
jects were male. All participants were interviewed, underwent a brief
medical examination and donated fasting blood samples at an examina-
tion which took place 3 months after the cardiac event for the patients.
Details of recruitment, representativeness and basic characteristics of
the groups have been published earlier [23]. The study was approved
by the ethics committee of the Karolinska University Hospital, and
conducted in agreement with the Declaration of Helsinki. All patients
and control persons gave their informed consent to participation.2.2. Coronary angiography
Routine coronary angiography was performed in a subset of 243
patients during the initial hospital stay (n = 35) or 3 months after the
cardiac event (n = 208) [23]. Angiograms were analyzed by quantita-
tive computer-based evaluation (QCA; Medis QCA-CMS system, Lei-
den). Minimal lumen diameter, reference diameter, percentage
diameter stenosis, mean segment diameter, segment length, plaque
area, segment area and number of signiﬁcant stenoses (N50%) were
registered in each of the 15 coronary segments.2.3. Biochemical analysis
Analyses of C-reactive protein (CRP) [24], plasminogen activator
inhibitor-1 (PAI-1) [23], matrix metalloproteinase-3 (MMP-3) [23]
and MMP-9 [25] have been the subject of previous reports.
2.4. ELISA for autoantibodies against native and MDA-modiﬁed collagen
type IV
Proteins were MDA-modiﬁed at 37 °C during 3 h in a solution using
0.05 mol/L MDA in PBS, pH 7.4. MDAmodiﬁcations were assayed using
thiobarbituric acid reactive substances assay (TBARS) andWestern blot
using antiMDA antibody. Antibodies in plasma against native andMDA-
modiﬁed collagen IV were detected by ELISA, essentially as described
[26]. Brieﬂy, 10 μg/mL of native or MDA-modiﬁed collagen IV was coat-
ed on microtiter plates (Nunc MaxiSorp, Roskilde, Denmark) and
blocked with Superblock in Tris buffered saline (Pierce, Rockford, IL,
USA). Plasma (dilution 1:100) was added to the wells and detection of
bound antibodies was done with biotinylated rabbit anti-human IgG
(Abcam) or IgM (Dako, Stockholm, Sweden), followed by alkaline
phosphatase-conjugated streptavidin (Sigma), and alkaline phospha-
tase substrate kit (Pierce). Absorbance from wells coated with native
collagen type IV was subtracted with absorbance from PBS-coated
wells. Absorbance from wells coated with MDA-collagen type IV was
subtracted with absorbance from wells coated with native collagen
type IV to exclude antibodies binding to native epitopes of MDA-
modiﬁed collagen type IV. Absorbance values were normalized against
a plasma pool present on each plate. Arbitrary units (AU) are deﬁned
as percentage of the absorbance to the plasma pool. Intra-assay (n =
10) and inter-assay (n = 10) coefﬁcients of variation for the antibody
ELISA directed against native collagen IV were 2.6 and 7.6% for the IgM
and 4.5 and 6.1% for the IgG, respectively. Intra-assay (n = 10) and
inter-assay (n = 10) coefﬁcients of variation for the antibody ELISA
directed against MDA-modiﬁed collagen IV were 7.0 and 5.5% for the
IgM and 11.9 and 10.2% for the IgG, respectively. Absorbance for anti-
bodies against collagen type IVwas in general low, but detectable levels
were present in 592 individuals for IgM against native collagen type IV,
in 89 individuals for IgG to native collagen type IV, in 536 individuals for
IgM against MDA-collagen type IV, and in 723 individuals for IgG to
MDA-collagen type IV, out of a total of 747 individuals. The speciﬁcities
of ELISAs were determined by competition assay. Binding of both IgM
and IgG in plasma to native collagen type IV was completely inhibited
by the addition of 100 μg/mL native collagen type IV, whereas addition
ofMDA-collagen type IVdid not compete (IgM)or only partly competed
out the interaction (IgG) (Supplementary Fig. 1A). Binding of IgM and
IgG in plasma to MDA-collagen type was completely inhibited by the
addition of 100 μg/mL MDA-collagen type IV, whereas native collagen
type IV or MDA-modiﬁed albumin did not compete or competed to a
lesser extent (Supplementary Fig. 1A).
2.5. Statistical methods
Owing tomissing samples in 19 patients and 8 controls, 368 patients
and 379 controls were available for subsequent statistical analysis. For
all types of antibodies (except IgG against native collagen type IV)
values under the detection limit were replaced with 0 values. Variables
are summarized as number (percentage) or medians (interquartile
range). Differences in group comparisons were assessed by using
Mann–Whitney test for continuous traits, and by Pearson's chi-
squared test for binary. Detectable levels of IgG against native collagen
type IV for patients and control individuals are summarized as group
percentages and are compared using chi-square test. In univariable
analysis, skewed data were transformed prior to analysis: anti-
collagen IV IgM was divided into 5 groups (values below the detection
limit, and 4 quartiles of positive values), anti-MDA-collagen IV IgM
and IgG underwent square-root transformation. Anti-collagen IV IgG
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above or below the limit of detection. The Jonckheere–Terpstra test for
ordered alternatives was used to assess trends by quartiles of speciﬁc
antibodies against collagen type IV. The associations between autoanti-
bodies against native and MDA-modiﬁed collagen type IV and MI were
determined by logistic regression analysis and calculation of odds ratios
with 95% conﬁdence intervals. Risk-adjusted models included
established cardiovascular risk factors. Despite that the entire study
population was controlled by age and sex, these two parameters were
always adjusted for while analyzing subsets of cases and controls.
Covariates with skewed distribution were log-transformed before
being entered in regression analysis. Correlations were performed
using Spearman rank test. Smoking habits are presented as current
smokers vs former or never smokers. A two-sided p-value b 0.05 was
considered signiﬁcant for all analyses. Statistical analyses were per-
formed using STATA 11.1 (Stata Corporation, USA).
3. Results
3.1. Increased levels of autoantibodies against native collagen type IV, but
lower levels of autoantibodies against MDA-collagen type IV, in patients
with MI
To determine whether auto-antibodies against collagen type IV in
plasma are associated with MI, we measured IgM and IgG against na-
tive and MDA-modiﬁed collagen type IV in cases and controls. Basic
characteristics of the groups are shown in Table 1. IgM levels against
native collagen type IV were increased in subjects who had suffered
MI (71 (31–125) AU) compared with healthy controls (42 (2.4–98)
AU; p b 0.001) (Table 1). IgG antibodies recognizing native collagen
type IVwere not detected in most samples. However, among individ-
uals with detectable levels of IgG against native collagen type IV,Table 1
Characteristics of study sample.
Patients
n = 368
Controls
n = 379
p-Valuea
Age (year) 54 (49–57) 54 (50–57) 0.35
Gender (% male) 83.7 83.6 0.98
Current smoking (% smokers) 20.3 22.6 0.2674
Lipid-lowering medication (%) 33.3 0 b0.001
BMI (kg/m2) 27 (25–30) 26 (24–28) b0.001
SBP (mm Hg) 130 (118–140) 128 (118–140) 0.73
DBP (mm Hg) 80 (75–87) 80 (78–88) 0.093
Triacylglycerols (mmol/L) 1.6 (1.2–2.3) 1.2 (0.8–1.6) b0.001
LDL cholesterol (mmol/L) 3.2 (2.5–3.9) 3.9 (3.3–4.5) 0.0001
HDL cholesterol, men (mmol/L) 0.8 (0.7–1.0) 1.1 (0.9–1.3) b0.001
HDL cholesterol, women
(mmol/L)
1.15 (0.95–1.4) 1.5 (1.25–1.75) b0.001
Glucose (mmol/L) 5.0 (5.3–5.9) 4.8 (4.6–5.2) b0.001
Insulin (pmol/L) 46.5
(32.0–69.0)
36.0
(28.0–49.0)
b0.001
Proinsulin (pmol/L) 5.1 (3.4–7.4) 3.5 (2.6–5.4) b0.001
C-reactive protein (mg/L) 1.5 (0.7–3.4) 1.0 (0.5–1.8) b0.001
IL-6 (ng/L) 0.8 (0.6–1.4) 0.6 (0.5–1.0) b0.001
Fibrinogen (g/L) 3.8 (3.3–4.3) 3.5 (3.1–4.0) b0.001
PAI-1 (IU/ml) 13.1 (4.8–22.6) 7.5 (3.1–17.8) b0.001
Anti-collagen IV IgM (AU) 71 (31–125) 42 (2.4–98) b0.001
Anti-collagen IV IgGb 17.2 6.7 b0.001
Anti-MDA-collagen IV IgM (AU) 36 (15–71) 39 (17–78) 0.14
Anti-MDA-collagen IV IgG (AU) 75 (55–104) 88 (60–123) b0.01
Basic characteristics of patients and controls of the entire cohort were originally reported
by Samnegård et al. [23]. Values are expressed asmedian (interquartile range) or percent-
age. Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; LDL, low-density lipoproteins; HDL, high-density lipoproteins; IL-6, inter-
leukin 6; PAI-1, plasminogen activator inhibitor-1; AU, arbitrary units; MDA,
malondialdehyde.
a p-Valueswere calculatedbyMann–WhitneyU test for continuous traits andbyPearson's
chi-squared test for binary variables.
b Values are expressed as percentage of individualswith detectable levels of IgG against
native collagen type IV, and differences were compared using Pearson's chi-square test.patients predominated over controls (17% of patients vs 6.7% of con-
trols; p b 0.001, Table 1). In contrast, analysis of auto-antibodies
against MDA-modiﬁed collagen type IV revealed that IgG antibodies
were lower in patients (75 (55–104) AU) than in controls (88 (60–
123) AU; p = 0.002, Table 1). IgM against MDA-modiﬁed collagen
type IV, on the other hand, did not differ signiﬁcantly between pa-
tients and controls (Table 1). Antibody levels were not associated
with any coronary angiography measurements.
3.2. Autoantibodies against native collagen type IV are independently
associated with MI
In multivariable logistic regression analysis, both IgM and IgG
against native collagen type IVwere associatedwithMI, and these asso-
ciations were independent of established cardiovascular risk factors
(p≤ 0.001 for both IgM and IgG). Detectable levels of IgG against native
collagen type IV were associated with a considerably higher risk of
having suffered MI (OR 2.9 (1.6–5.4), p = 0.001 after adjusting for car-
diovascular risk factors). Dividing IgM against native collagen type IV
into quartiles revealed that the highest quartile of IgM against native
collagen type IV was associated with a substantially increased risk of
having contracted MI (OR 3.11 (1.8–5.4) for 4th vs 1st quartile,
p b 0.001 after adjusting for risk factors; Table 2).
In univariable logistic regression analysis, IgM and IgG againstMDA-
modiﬁed collagen type IV were associated with MI (p = 0.046 for IgM
and p = 0.008 for IgG), however these associations did not remain
after adjusting for established risk factors. Dividing IgG against MDA-
collagen type IV into quartiles showed that a high level of IgG against
MDA-collagen type IV was associated with decreased risk of MI (OR
0.61 (0.40–0.91) for 4th vs 1st quartile, p = 0.002; Table 2). Again,
this association did not remain statistically signiﬁcant after adjusting
for cardiovascular risk factors (p = 0.09, Table 2).
3.3. Association of autoantibodies to cardiovascular risk factors with
inﬂammatory and thrombotic markers
Autoantibodies against native or MDA-collagen type IV did not
correlate signiﬁcantly with smoking, body-mass index, systolic
blood pressure, diastolic blood pressure, plasma glucose, insulin,
LDL- or HDL-cholesterol, or CRP, except for an inverse association
between IgG against native collagen type IV and HDL-cholesterol
(r =−0.13, p b 0.001).Table 2
Odds ratios for risk of myocardial infarction by quartiles of IgM against native collagen
type IV or IgG against MDA-collagen type IV.
Myocardial infarction Q1 Q2 Q3 Q4 p for trend
Odds ratio (95% CI)
IgM native coll IV
Unadjusted 1 1.45
(0.96–2.2)
2.28
(1.5–3.4)⁎⁎
2.46
(1.6–3.7)⁎⁎
0.001
Risk factor
adjusteda
1 1.72
(0.99–3.0)
2.92
(1.7–5.1)⁎⁎
3.11
(1.8–5.4)⁎⁎
0.002
IgG MDA coll IV
Unadjusted 1 1.09
(0.73–1.6)
0.65
(0.43–0.98)⁎
0.61
(0.40–0.91)⁎
0.002
Risk factor
adjusteda
1 1.35
(0.79–2.3)
0.70
(0.41–1.2)
0.61
(0.36–1.0)
0.09
Values are odds ratios (95% conﬁdence intervals) in quartiles (Q1–Q4) of IgM against
native collagen type IV or IgG against MDA-collagen type IV, respectively. Two-sided p-
values calculated by Jonckheere–Terpstra trend test. The stars represent signiﬁcant
differences between the corresponding quartile and a reference Q1 (Mann–Whitney
test). Coll IV, collagen type IV; CRP; C-reactive protein; HDL, high-density lipoproteins;
LDL, low density lipoproteins; MDA, malondialdehyde.
⁎ p b 0.05.
⁎⁎ p b 0.001.
a Adjusted to age, sex, height, smoking, diastolic blood pressure, hypertension, glucose,
LDL-cholesterol, HDL-cholesterol, triglycerides and CRP.
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associations of PAI-1 with IgM against both native and MDA-collagen
type IV. The lower quartile of IgM against native collagen type IV was
associated with decreased levels of PAI-1 (quartile 1 vs quartiles 2–4,
p = 0.004) in the entire cohort. In contrast, the upper quartile of IgM
against MDA-modiﬁed collagen type IV was associated with decreased
levels of PAI-1 (quartiles 1–3 vs quartile 4, p = 0.027). This difference
remained statistically signiﬁcant in controls (p = 0.025), but not in
patients.
In addition, there was a signiﬁcant negative trend between quartiles
of IgM against native collagen type IV and MMP-3-levels (p = 0.003).
The highest quartile of IgM against native collagen type IV displayed
decreased levels of MMP-3 in the entire cohort (p = 0.0015) and in
cases (p = 0.015), whereas no signiﬁcant association was observed in
controls (p= 0.21) (Fig. 1A). The highest quartile of IgM against native
collagen type IV was also associated with decreased of levels of MMP-9
in the entire cohort (p = 0.0061). This association was stronger in
controls (p = 0.058) than in cases (p = 0.51) (Fig. 1B). In contrast to
antibodies against the native protein, the upper quartile of IgM against
MDA-collagen type IV displayed increased levels of MMP-9 in the entire
cohort (p= 0.0099) and in controls (p= 0.030), whereas there was no
signiﬁcant difference in cases (p = 0.15) (Fig. 1C).
4. Discussion
Collagen type IV is the most abundant collagen in basement mem-
branes and is considered to be responsible for their mechanical stability
[27]. Collagen type IV is also essential for cell adhesion and cell-matrixFig. 1. IgM antibodies against native collagen type IV are associatedwith decreased levels of circu
increased levels ofMMP-9. IgMagainst native (A, B) andMDA-collagen type IV (C)were divided
or controls were calculated by Mann–Whitney test.communication and plays an important role in maintaining endothelial
cell function. In this communication, we report that circulating IgM and
IgG autoantibodies against native collagen type IV are increased in
patients with recent MI and that these associations are independent of
major cardiovascular risk factors. Moreover, autoantibodies against
native collagen type IV were associated with a substantially increased
risk of having contracted MI.
Autoantibodies against collagen type IV have been found in autoim-
mune diseases such as Goodpasture syndrome and Alport post-
transplant nephritis. In both examples, type IV collagen is affected either
bymutations or immune response leading to kidney and/or lung failure.
In Goodpasture syndrome autoantibodies against collagen type IV are
directed against epitopes in the non-collagenous-1 (NC1)-domain,
which are exposed due to dissociation (or failure of association) of
collagen type IV hexamers [10,11]. Interestingly, local environmental
factors such as endogenous oxidants and tobacco smoke are presumed
to play a role in the dissociation of collagen type IV hexamers. Rheumat-
ic fever is characterized by inﬂammatory changes in subendothelial and
perivascular collagen tissue. According to a recent hypothesis, the
carditis of rheumatic fever results from an immune response against
collagen type IV, affecting the overlying endothelium [12]. It has previ-
ously been shown that streptococcal protein, causing rheumatic fever,
binds to collagen type IV. Moreover, serum from patients with acute
rheumatic fever contained increased titers of anti-collagen type IV anti-
bodies [9]. In our study, IgM collagen type IV antibodies were present in
80% of the study population, whereas detectable levels of IgG were
present in about 10% of the 747 individuals.Why autoantibodies against
native collagen type IV were present in a signiﬁcant proportion oflatingMMP-3 andMMP-9, whereas IgM againstMDA-collagen type IV are associatedwith
in quartiles and differences inMMP-3 (A) andMMP-9 (B, C) including all individuals, cases
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ELISA technique identiﬁed increased levels of IgG antibodies against
collagen type IV in idiopathic dilated cardiomyopathy, but not in pa-
tients with acute MI [28]. IgG antibodies against collagen type IV were
present in 18% of the MI patients one day after hospitalization, which
decreased to 14% after two weeks. These numbers are in agreement
with the presence of IgG against native collagen type IV in 17% of the
MI patients in our cohort. The lack of difference between IgG against col-
lagen type IV in MI patients versus controls in the previous study, may
be due to the small number of subjects analyzed (20 MI patients and
20 controls).
Previous studies in an experimental ratMImodel showed that colla-
gen type IV together with laminin and collagen type III are present rel-
atively early afterMI [29–32].Moreover, collagen type IVwas present in
the infarct zone, not restricted to basement membranes, indicating that
collagen type IV contributes to the healing process. Whether antibodies
against native collagen type IV inﬂuence or may be markers of infarct
healing remains to be studied.
Modiﬁcations of collagen type IV are likely to disturb its interactions
with endothelial cells and basement membrane components, resulting
in an impaired basement membrane structure and endothelial cell dys-
function. For example, glycosylation of collagen type IV affects assembly
of collagen type IV networks [33] and causes endothelial cell detach-
ment and decreases endothelial cell adhesion and spreading [34,35].
Of note, it has been shown that modiﬁcation of laminin, the other
major basement membrane component, with reactive oxygen species
induced increased monocyte attachment and expression of ICAM-1 on
endothelial cells [21]. Thus, autoantibodies againstMDA-modiﬁed colla-
gen type IV may serve a protective function by facilitating removal of
modiﬁed collagen type IV or simply by blockingmodiﬁed sites. In agree-
ment with this, autoantibodies against MDA-collagen type IV were
found to be increased in controls compared with patients, although
this difference was not independent of cardiovascular risk factors.
High levels of IgM against native collagen type IV were associated
with lower levels of MMP-3 and MMP-9. Expression of MMPs in the
ﬁbrous cap is likely to result in increased risk of plaque rupture, which
would argue against negative association to autoantibodies recognizing
native collagen type IV. On the other hand, MMPs could contribute to
plaque stability by facilitating smoothmuscle cell migration. According-
ly, deletion of MMP-3 and MMP-9 in apoE−/− mice resulted in larger
lesions and amore unstable plaque phenotypewith less smoothmuscle
cells [36]. Interestingly, MMPs also play a role in thrombosis; e.g. MMP-
9 has been shown to inhibit platelet aggregation in response to throm-
bin or collagen and to degrade ﬁbrin [37,38]. Clinical studies of plasma
MMP-3 andMMP-9 identify MMP-3 as a biomarker negatively associat-
ed with coronary events, whereasMMP-9 instead is positively associat-
edwith coronary events. In the present cohort, bothMMP-3 andMMP-9
were found to be lower in patients than in controls [23,25], which is in
agreement with the inverse relationship of autoantibodies against
native collagen type IV and MMP-3 and -9.
A limitation of the study is that is does not address the question of
whether the antibodies are markers of disease or indeed play a func-
tional role. It is possible that autoantibodies against collagen type IV
are induced when plaque components are exposed to the circulating
immune system upon rupture of the lesions. This question needs to be
addressed in further studies including additional cohorts.
5. Conclusion
In conclusion, we show that autoantibodies against native collagen
type IV are associated with myocardial infarction independently of tra-
ditional cardiovascular risk factors, suggesting a break of tolerance.
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